Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jan 24:13:11.
doi: 10.1186/1471-2377-13-11.

Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial

Stefanie Leistner  1 , Georg Michelson, Inga Laumeier, Michael Ahmadi, Maureen Smyth, Gabriele Nieweler, Wolfram Doehner, Jan Sobesky, Jochen B Fiebach, Peter Marx, Otto Busse, Friedrich Köhler, Holger Poppert, Martin L J Wimmer, Thomas Knoll, Paul Von Weitzel-Mudersbach, Heinrich J Audebert
Affiliations
Randomized Controlled Trial

Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial

Stefanie Leistner et al. BMC Neurol. .

Abstract

Background: Patients with recent stroke or TIA are at high risk for new vascular events. Several evidence based strategies in secondary prevention of stroke are available but frequently underused. Support programs with multifactorial risk factor modifications after stroke or TIA have not been investigated in large-scale prospective controlled trials so far. INSPiRE-TMS is a prospective, multi-center, randomized open intervention trial for intensified secondary prevention after minor stroke and TIA.

Methods/design: Patients with acute TIA or minor stroke admitted to the participating stroke centers are screened and recruited during in-hospital stay. Patients are randomised in a 1:1 ratio to intervention (support program) and control (usual care) arms. Inclusion of 2.082 patients is planned. The support program includes cardiovascular risk factor measurement and feedback, monitoring of medication adherence, coaching in lifestyle modifications, and active involvement of relatives. Standardized motivational interviewing is used to assess and enhance patients' motivation. Primary objective is a reduction of new major vascular events defined as nonfatal stroke and myocardial infarction or vascular death. Recruitment time is planned for 3.5 years, follow up time is at least 2 years for every patient resulting in a total study time of 5 years (first patient in to last patient out).

Discussion: Given the high risk for vascular re-events in acute stroke and the available effective strategies in secondary prevention, the INSPIRE-TMS support program has the potential to lead to a relevant reduction of recurrent events and a prolongation of the event-free survival time. The trial will provide the basis for the decision whether an intensified secondary prevention program after stroke should be implemented into regular care. A cost-effectiveness evaluation will be performed.

Trial registration: clinicaltrials.gov: 01586702.

Trial registration: ClinicalTrials.gov NCT01586702.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of study procedures.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041. - PubMed
    1. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA. et al.Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–1251. doi: 10.1056/NEJMoa0805002. - DOI - PMC - PubMed
    1. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE. et al.High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559. - PubMed
    1. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL. et al.International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189. doi: 10.1001/jama.295.2.180. - DOI - PubMed
    1. Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P. et al.Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis. 2008;25:366–374. doi: 10.1159/000120687. - DOI - PubMed

Publication types

Associated data